After flying high during the first half of the year, pharmaceutical giant Eli Lilly (NYSE: LLY) has lost some momentum; the ...

LLY's recent sell-off presents a buying opportunity for savvy investors, with strong growth potential in the GLP-1 market ...

From there, the case for or against investing in Lilly should become much clearer. Eli Lilly's earnings report ...

Madison Investments, an investment advisor, released its “Madison Sustainable Equity Fund” third quarter 2024 investor letter ...

Nov. 20, 2024 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company pioneering the use of artificial intelligence (AI) and human data to transfo Eli Lilly and Company (NYSE ...

Eli Lilly faces challenges with slowing drug sales and a lawsuit against the HRSA. Learn why caution is advised for LLY stock despite its lower P/E ratio.

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

Arguably, no big pharma stocks have dominated the industry more over the last few years than Eli Lilly (NYSE: LLY) and Pfizer ...

The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...

Eli Lilly and Company (NYSE: LLY) announced today that it has elected Jon Moeller as a new member of its board of directors ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and ...

Conditions are getting a bit more challenging for the drugmaker.